{"id":15367,"date":"2011-04-12T05:04:38","date_gmt":"2011-04-12T09:04:38","guid":{"rendered":"http:\/\/asweetlife.org\/?p=15367"},"modified":"2015-12-30T03:38:22","modified_gmt":"2015-12-30T08:38:22","slug":"sanofi-aventis-says-new-lixisenatide-shows-promise","status":"publish","type":"post","link":"https:\/\/asweetlife.org\/?p=15367","title":{"rendered":"Sanofi-aventis Announces Positive Results for Lixisenatide"},"content":{"rendered":"<p style=\"text-align: justify;\"><a href=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/04\/sanofi-aventis-logo1.jpg\" rel=\"mfp\"><img decoding=\"async\" class=\"alignleft size-medium wp-image-15370 lazyload\" title=\"sanofi-aventis-logo\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" data-src=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/04\/sanofi-aventis-logo1-300x158.jpg\" alt=\"\" width=\"180\" height=\"95\" \/><\/a>Sanofi-aventis announced today that lixisenatide, a once-daily GLP-1 receptor agonist under development for people with type 2 diabetes, achieved its primary efficacy objective of significant HbA1c reduction and improved glycemic control from baseline versus placebo. The results also showed that people treated with lixisenatide had a significant decrease in body weight, and that lixisenatide did not significantly increase the risk of symptomatic hypoglycemia compared with a placebo.<\/p>\n<p style=\"text-align: justify;\">GLP-1 is a naturally occurring body hormone that helps to maintain normal blood sugar levels.\u00a0 Patients with type 2 diabetes have defects in their GLP-1 system that contribute to inadequate insulin release which, in turn, result in increased glucose levels. GLP-1 drugs suppress glucagon secretion by the pancreatic alpha cells and stimulate insulin release by the pancreatic beta cells when glucose levels become too high.<\/p>\n<p style=\"text-align: justify;\">Sanofi&#8217;s diabetes offering currently includes the Lantus, a long-acting insulin, as well as the rapid-acting insulin Apidra.\u00a0 If Lixisenatide wins marketing approval it will compete with other GLP-1 receptor agonists, Novo Nordisk&#8217;s <a href=\"https:\/\/asweetlife.org\/a-sweet-life-staff\/in-the-news\/type-2-in-the-news\/a-sweet-life-staff\/featured\/all-about-victoza-an-interview-with-novo-nordisks-dr-alan-moses\/9219\/\" target=\"_blank\">Victoza<\/a> and Amylin and Eli Lilly&#8217;s Byetta.\u00a0 In November 2010, Novo <a href=\"http:\/\/www.reuters.com\/article\/2010\/11\/09\/us-summit-novonordisk-idUSTRE6A844720101109\" target=\"_blank\">announced<\/a> it expected annual Victoza sales to reach $1 billion by 2012.<\/p>\n<p style=\"text-align: justify;\">\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sanofi-aventis announced today that lixisenatide, a once-daily GLP-1 receptor agonist under development for people with type 2 diabetes, achieved its primary efficacy objective of significant HbA1c reduction and improved glycemic control from&#8230;<\/p>\n","protected":false},"author":131,"featured_media":15370,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1443],"tags":[1072],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.9 (Yoast SEO v22.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Sanofi-aventis New Type 2 Diabetes Drug, Lixisenatide, Shows Promise<\/title>\n<meta name=\"description\" content=\"Sanofi-aventis announced today that lixisenatide, a once-daily GLP-1 receptor agonist under development for people with type 2 diabetes, achieved significant HbA1c reduction and improved glycemic control.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/asweetlife.org\/?p=15367\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ASweetLife Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/asweetlife.org\/?p=15367\",\"url\":\"https:\/\/asweetlife.org\/?p=15367\",\"name\":\"Sanofi-aventis New Type 2 Diabetes Drug, Lixisenatide, Shows Promise\",\"isPartOf\":{\"@id\":\"https:\/\/asweetlife.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/asweetlife.org\/?p=15367#primaryimage\"},\"image\":{\"@id\":\"https:\/\/asweetlife.org\/?p=15367#primaryimage\"},\"thumbnailUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/04\/sanofi-aventis-logo1.jpg\",\"datePublished\":\"2011-04-12T09:04:38+00:00\",\"dateModified\":\"2015-12-30T08:38:22+00:00\",\"author\":{\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\"},\"description\":\"Sanofi-aventis announced today that lixisenatide, a once-daily GLP-1 receptor agonist under development for people with type 2 diabetes, achieved significant HbA1c reduction and improved glycemic control.\",\"breadcrumb\":{\"@id\":\"https:\/\/asweetlife.org\/?p=15367#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/asweetlife.org\/?p=15367\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/?p=15367#primaryimage\",\"url\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/04\/sanofi-aventis-logo1.jpg\",\"contentUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/04\/sanofi-aventis-logo1.jpg\",\"width\":656,\"height\":347,\"caption\":\"sanofi-aventis-logo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/asweetlife.org\/?p=15367#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/asweetlife.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi-aventis Announces Positive Results for Lixisenatide\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/asweetlife.org\/#website\",\"url\":\"https:\/\/asweetlife.org\/\",\"name\":\"ASweetLife\",\"description\":\"The Diabetes Magazine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/asweetlife.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\",\"name\":\"ASweetLife Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"caption\":\"ASweetLife Team\"},\"url\":\"https:\/\/asweetlife.org\/?author=131\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanofi-aventis New Type 2 Diabetes Drug, Lixisenatide, Shows Promise","description":"Sanofi-aventis announced today that lixisenatide, a once-daily GLP-1 receptor agonist under development for people with type 2 diabetes, achieved significant HbA1c reduction and improved glycemic control.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/asweetlife.org\/?p=15367","twitter_misc":{"Written by":"ASweetLife Team","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/asweetlife.org\/?p=15367","url":"https:\/\/asweetlife.org\/?p=15367","name":"Sanofi-aventis New Type 2 Diabetes Drug, Lixisenatide, Shows Promise","isPartOf":{"@id":"https:\/\/asweetlife.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/asweetlife.org\/?p=15367#primaryimage"},"image":{"@id":"https:\/\/asweetlife.org\/?p=15367#primaryimage"},"thumbnailUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/04\/sanofi-aventis-logo1.jpg","datePublished":"2011-04-12T09:04:38+00:00","dateModified":"2015-12-30T08:38:22+00:00","author":{"@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585"},"description":"Sanofi-aventis announced today that lixisenatide, a once-daily GLP-1 receptor agonist under development for people with type 2 diabetes, achieved significant HbA1c reduction and improved glycemic control.","breadcrumb":{"@id":"https:\/\/asweetlife.org\/?p=15367#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/asweetlife.org\/?p=15367"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/?p=15367#primaryimage","url":"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/04\/sanofi-aventis-logo1.jpg","contentUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/04\/sanofi-aventis-logo1.jpg","width":656,"height":347,"caption":"sanofi-aventis-logo"},{"@type":"BreadcrumbList","@id":"https:\/\/asweetlife.org\/?p=15367#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/asweetlife.org\/"},{"@type":"ListItem","position":2,"name":"Sanofi-aventis Announces Positive Results for Lixisenatide"}]},{"@type":"WebSite","@id":"https:\/\/asweetlife.org\/#website","url":"https:\/\/asweetlife.org\/","name":"ASweetLife","description":"The Diabetes Magazine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/asweetlife.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585","name":"ASweetLife Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","caption":"ASweetLife Team"},"url":"https:\/\/asweetlife.org\/?author=131"}]}},"_links":{"self":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/15367"}],"collection":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15367"}],"version-history":[{"count":0,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/15367\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/media\/15370"}],"wp:attachment":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15367"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15367"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15367"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}